Inhibition of phospholipase A2 as a therapeutic target

Saul Yedgar*, Dov Lichtenberg, Edit Schnitzer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The hydrolysis of cell membrane phospholipids by phospholipase A2 (PLA2) leads to the production of numerous lipid mediators of diverse pathological conditions, mainly inflammatory diseases. These include lysophospholipids and their derivatives, and arachidonic acid and its derivatives (the eicosanoids). Both these groups of mediators are produced predominantly by the secretory PLA2s (sPLA2s) which hydrolyze the phospholipids of the cell surface membrane. Protection of cell membrane from these 'inflammatory enzymes' can therefore be used for the treatment of inflammatory processes. A prototype of cell-impermeable PLA2 inhibitors, which protect the cell membrane from different sPLA2s without affecting vital phospholipid metabolism, is presented and discussed in the present review. (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)182-187
Number of pages6
JournalBiochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Volume1488
Issue number1-2
DOIs
StatePublished - 31 Oct 2000

Keywords

  • Anti-inflammatory drug
  • Cell-impermeable PLA inhibitor
  • Eicosanoid
  • Inflammatory process
  • Inhibition of PLA
  • Phospholipase A
  • Secretory PLA

Fingerprint

Dive into the research topics of 'Inhibition of phospholipase A2 as a therapeutic target'. Together they form a unique fingerprint.

Cite this